Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Unraveling progression predictors in prefibrotic myelofibrosis: A 2,000-patient systematic review and meta-analysis

Nency Ganatra, Pragya Jain, Shivam Patel et al. Nov 03, 2025 pp. 7271-7271 10.1182/blood-2025-7271

Abstract Background: Prefibrotic primary myelofibrosis (pre-PMF) is a distinct clinical entity within the myeloproliferative neoplasms (MPNs...

A new pathogenic variant red cell membrane defect resulting in chronic hemolytic anemia

Robert Eisner, Mehraboon Irani, David Grinblatt Nov 03, 2025 pp. 6449-6449 10.1182/blood-2025-6449

Abstract Hereditary Pyropoikilocytosis (HPP) is a red blood cell membrane defect characterized by severe and symptomatic hemolytic anemia. T...

Elevated risk of non-neoplastic mortality among adolescent and young adult patients with low-grade B-cell lymphoma

Rahul Mishra, Sachi Singhal, Harshank Patel et al. Nov 03, 2025 pp. 3613-3613 10.1182/blood-2025-3613

Abstract Background Adolescent and young adult (AYA) patients with low-grade B-cell lymphoma/leukemia (LoGL) typically have favorable cancer-...

The relationship of social support and psychosocial complexity with chimeric antigen receptor T-cell therapy outcomes

Jessica Nino de Rivera, Shruthi Venkatachalam, Kyle Karpinski et al. Nov 03, 2025 pp. 4544-4544 10.1182/blood-2025-4544

Abstract Background: Chimeric antigen receptor T-cell therapy (CAR-T) is a transformative therapy for relapsed/refractory hematologic malign...

Inpatient vs outpatient treatment management with teclistamab in relapsed and refractory multiple myeloma: A cost and healthcare resource utilization analysis

Niels W.C.J. van de Donk, Ruth Wester, Inger Nijhof et al. Nov 03, 2025 pp. 7936-7936 10.1182/blood-2025-7936

Abstract Introduction: Teclistamab is a first-in-class bispecific antibody targeting CD3 on T-cells and B-cell maturation antigen (BCMA) on...

Real‑world experience with anti‑TFPI agent (Marstacimab) in severe and non‑severe hemophilia: First reported successful use in a female with non-severe hemophilia b

Akshat Jain Nov 03, 2025 pp. 3068-3068 10.1182/blood-2025-3068

Abstract We report results of the first real world study evaluating outcomes in people with severe and non-severe hemophilia (SH, NSH), incl...

Consensus on optimal use of fixed-duration BTK inhibitor and venetoclax therapy in CLL: A delphi study comparing human expertise and AI methodologies

Giuliana Farina, Mariano Lucignano, Maria Rosaria Villa et al. Nov 03, 2025 pp. 7434-7434 10.1182/blood-2025-7434

Abstract Background: In the context of fixed-duration (FD) Bruton's tyrosine kinase inhibitor (BTKi) and B-Cell Lymphoma 2 inhibitor (BCL2i)...

Deciphering the cellular hierarchy of multiple myeloma uncovers a therapeutically exploitable EP300/TBX2 axis in LILRB4+ myeloma-initiating cells

Haoguang Chen, Shanshan Pei, Qiqi Shen et al. Nov 03, 2025 pp. 2170-2170 10.1182/blood-2025-2170

Abstract Background: In contrast to leukemia, where the cancer stem cell model has clearly explained tumor hierarchies, multiple myeloma (MM...

Large B-cell lymphoma after CD19-CAR-T failure: Updated real-world outcomes, prognostic factors, and prediction models

Smith Kungwankiattichai, Sanjog Bastola, Manoj Rai et al. Nov 03, 2025 pp. 3726-3726 10.1182/blood-2025-3726

Abstract Background While CD19-CAR-T cell therapy has revolutionized treatment for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), a...

Improved Survival outcomes with allo-HSCT in NUP214::ABL1-Positive Acute leukemia: A pooled analysis and single-center experience

Jiu-jiang He, Jing Long, Qian Yang et al. Nov 03, 2025 pp. 4258-4258 10.1182/blood-2025-4258

Abstract Introduction The NUP214::ABL1 fusion gene, resulting from the fusion of nucleoporin NUP214 and the tyrosine kinase ABL1, harbors ki...

Clinical characteristics and outcomes of cerebral venous sinus thrombosis in hematologic malignancy patients pre- and post-hematopoietic stem cell transplantation: A single-center retrospective study in China

Juanjuan Li, Hai-Xia Fu, Yuanyuan Zhang et al. Nov 03, 2025 pp. 3126-3126 10.1182/blood-2025-3126

Abstract Introduction: Cerebral venous sinus thrombosis (CVST) is a rare but life-threatening complication in patients w...

INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy

Justin Watts, Anthony Hunter, Junichiro Yuda et al. Nov 03, 2025 pp. 5574-5574 10.1182/blood-2025-5574

Abstract Background: The pathophysiology of myelofibrosis (MF) and other hematologic malignancies is modulated by the epigenetic reader brom...

Remote multi-vital sign monitoring allows earlier detection of cytokine release syndrome after bispecific T cell engager and chimeric antigen receptor T cell therapies

Chenyu Lin, Melinda Chen, Jingchen Chai et al. Nov 03, 2025 pp. 1075-1075 10.1182/blood-2025-1075

Abstract Introduction: Cytokine release syndrome (CRS) is a systemic inflammatory condition seen in 50-80% of patients after bispecific T ce...

Second-generation tyrosine kinase inhibitors vs imatinib in adult ph+ ALL: Target-trial emulation using a propensity-matched multinational cohort

Xiaoyi Zhang, Abhishek Kumar, Cho-Hao Lee et al. Nov 03, 2025 pp. 6856-6856 10.1182/blood-2025-6856

Abstract Background: Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph + ALL) accounts for 20–30 % of adult ALL and carries...

M6A-driven control of T cell fitness via lrpprc defines a novel regulatory axis to enhance adoptive cell therapy

Jeremy Meier, Aleksandra Petrova, Matthew Tegowski et al. Nov 03, 2025 pp. 5886-5886 10.1182/blood-2025-5886

Abstract Adoptive cellular therapies (ACT) including chimeric antigen receptor (CAR)-T cells have transformed the treatment landscape for pa...

Use of an oncology informatics knowledgebase to improve influenza vaccination rate in pediatric oncology patients

Renee Gresh, Kimberly Davidow, Jeffrey Myers et al. Nov 03, 2025 pp. 6429-6429 10.1182/blood-2025-6429

Abstract Introduction: It is well known that children with cancer are at an increased risk of severe influenza infections due to immunosuppr...

Overall response rates and progression free survival rates of bispecific antibodies vs CAR-T in the treatment of extramedullary disease and high-risk cytogenetics in relapsed multiple myeloma: A systematic review and meta-analysis

Charan Vegivinti, Nikhil Vojjala, Jaison Lawrence Alexander Santhi et al. Nov 03, 2025 pp. 7599-7599 10.1182/blood-2025-7599

Abstract Background: Bispecific antibodies (BsAb) and Chimeric antigen receptor T-cell therapy (CAR-T) have significantly transformed treatm...

High sensitivity mass spectrometry for multiple myeloma monitoring using microsampling: A patient-centered approach

Nithya Paranthaman, Katie Horton, Nicola Wright et al. Nov 03, 2025 pp. 8137-8137 10.1182/blood-2025-8137

Abstract Background: Microsampling presents a minimally invasive alternative to venipuncture, offering potential improvements in the routine...

A collective non-mutational transition governs the development of chronic myeloid leukemia

Richard Van Etten, Nilamani Jena, Prasanthi Tata et al. Nov 03, 2025 pp. 1984-1984 10.1182/blood-2025-1984

Abstract Introduction: The field of carcinogenesis has been dominated by the concept that cancer is caused by the accumulation of genetic mu...

Thymic dysfunction promotes the emergence of pathogenic peripheral CD4⁺CD8⁺ T cells and induces tissue injury in acute gvhd

Meng Zhang, Hengwei Wu, Xinyi Lai et al. Nov 03, 2025 pp. 4240-4240 10.1182/blood-2025-4240

Abstract Acute graft-versus-host disease (aGVHD) is one of the most severe complications following allogeneic hematopoietic stem cell transp...

Venetoclax enhances T cell fitness and CAR T-cell manufacturing potential in chronic lymphocytic leukemia (CLL)

Arun Arunachalam, Beatriz Coutinho De Oliveira, Celine Gregoire et al. Nov 03, 2025 pp. 2322-2322 10.1182/blood-2025-2322

Abstract IntroductionChronic lymphocytic leukemia (CLL) is marked by profound immune dysregulation, which compromises both the numerical and...

GATA-3 identifies a distinct subset of T-cell prolymphocytic leukemia (T-PLL) and is associated with CCR4 expression

Marc Gutierrez, Carlos Murga Zamalloa, Kedar Inamdar et al. Nov 03, 2025 pp. 1877-1877 10.1182/blood-2025-1877

Abstract Background: T-PLL is a rare mature T-cell malignancy. Despite improved understanding of disease pathogenesis, outcomes remain poor....

Antiviral efficacy of EBV and CMV bispecific cytotoxic t lymphocytes following allogeneic hematopoietic stem cell transplantation

Ruirui Gui, Zhen Li, Juan Wang et al. Nov 03, 2025 pp. 7646-7646 10.1182/blood-2025-7646

Abstract Purpose: To improve the cure rate of patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is cruc...

Nationwide and regional trends, outcomes, and cost of systemic thrombolysis,standard catheter-directed thrombolysis, and ultrasound-assisted thrombolysisfor pulmonary embolism

Emeka Agudile, Marina Khan, Danae Hamouda et al. Nov 03, 2025 pp. 4395-4395 10.1182/blood-2025-4395

Abstract Background: Pulmonary embolism (PE) is still a leading cause of morbidity and mortality in the United States (U...

The real-world safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy in systemic AL amyloidosis

Matthew Rees, Raffaella Cassano Cassano, Melinda Tan et al. Nov 03, 2025 pp. 2181-2181 10.1182/blood-2025-2181

Abstract Introduction: Achieving rapid and deep hematological responses is essential for improving organ function and reducing early mortali...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page